Patents by Inventor Takaharu Tsutsumi
Takaharu Tsutsumi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7557113Abstract: A compound having GSK-3 inhibitory activity. A1 and A3 are a single bond, an aliphatic hydrocarbon group; A2 and A4 are a single bond, CO, COO, CONR, O, OCO, NR, NRCO, NRCOO, etc.; G1 is a single bond, an aliphatic hydrocarbon, aromatic hydrocarbon, heterocyclic; G2 is H, an aliphatic hydrocarbon, an alicyclic hydrocarbon, an aromatic hydrocarbon, heterocyclic; A5 is a single bond, NR; R2 is H, halogen, an aliphatic hydrocarbon, alicyclic hydrocarbon, aromatic hydrocarbon, heterocyclic; A6 is a single bond, NR, CO, NRCO, NRCONR, CONR, COO, O, etc.; R3 is H, halogen, nitro, saturated aliphatic hydrocarbon, alicyclic hydrocarbon, aromatic hydrocarbon, heterocyclic; and R3 may be a trimethylsilyl, formyl, acyl, carboxyl, alkoxylcarbonyl, carbamoyl, alkylcarbamoyl, or cyano group when A6 is CR?CR or C?C, wherein R is H or an lower aliphatic hydrocarbon group.Type: GrantFiled: August 26, 2004Date of Patent: July 7, 2009Assignee: Teijin Pharma LimitedInventors: Takaharu Tsutsumi, Satoshi Sugiura, Masahiro Koga, Yoshiyuki Matsumoto, Toshihiro Ishii, Akira Nakano, Gen Unoki, Yuri Sakai, Reiko Takarada, Hiroko Ogawa
-
Patent number: 7528140Abstract: The invention provides pyrrolo[3,2-d]pyrimidine derivatives represented by formula (I), and their medically acceptable salts. The compounds of the invention exhibit GSK-3 inhibiting activity and are therefore expected to be useful as therapeutic or prophylactic agents for conditions in which GSK-3 is implicated, such as diabetes, diabetes complications, Alzheimer's disease, neurodegenerative diseases, manic depression, traumatic encephalopathy, alopecia, inflammatory diseases, cancer and immune deficiency.Type: GrantFiled: February 24, 2003Date of Patent: May 5, 2009Assignee: Teijin LimitedInventors: Kenichiro Kataoka, Tomomi Kosugi, Toshihiro Ishii, Takahiro Takeuchi, Takaharu Tsutsumi, Akira Nakano, Gen Unoki, Masanori Yamamoto, Yuri Sakai
-
Publication number: 20060160831Abstract: A compound having GSK-3 inhibitory activity. A1 and A3 are a single bond, an aliphatic hydrocarbon group; A2 and A4 are a single bond, CO, COO, CONR, O, OCO, NR, NRCO, NRCOO, etc.; G1 is a single bond, an aliphatic hydrocarbon, aromatic hydrocarbon, heterocyclic; G2 is H, an aliphatic hydrocarbon, an alicyclic hydrocarbon, an aromatic hydrocarbon, heterocyclic; A5 is a single bond, NR; R2 is H, halogen, an aliphatic hydrocarbon, alicyclic hydrocarbon, aromatic hydrocarbon, heterocyclic; A6 is a single bond, NR, CO, NRCO, NRCONR, CONR, COO, O, etc.; R3 is H, halogen, nitro, saturated aliphatic hydrocarbon, alicyclic hydrocarbon, aromatic hydrocarbon, heterocyclic; and R3 may be a trimethylsilyl, formyl, acyl, carboxyl, alkoxylcarbonyl, carbamoyl, alkylcarbamoyl, or cyano group when A6 is CR?CR or C?C, wherein R is H or an lower aliphatic hydrocarbon group.Type: ApplicationFiled: August 26, 2004Publication date: July 20, 2006Applicant: TEIJIN PHARMA LIMITEDInventors: Takaharu Tsutsumi, Satoshi Sugiura, Masahiro Koga, Yoshiyuki Matsumoto, Toshihiro Ishii, Akira Nakano, Gen Unoki, Yuri Sakai, Reiko Takarada, Hiroko Ogawa
-
Patent number: 7071359Abstract: A compound represented by the Formula below, and an agent for the remedy of neural damage having the said compound as the active ingredient. [Here, G represents G1 shown below R4 represents, hydrogen atoms and acyl groups, W represents single bonds and alkylenes, m represents 0 or 1, R5 and R6 represent hydrogen atoms, aliphatic hydrocarbon groups, alicyclic hydrocarbon groups, aromatic hydrocarbon groups and heterocyclic groups, and R7 represents hydrogen atoms, acyl groups and alkoxycarbonyl groups. A2 represents, single bonds, —O—, —NR3—, and —S(?O)n—, A1 and A3 represent single bonds, aliphatic hydrocarbon groups, alicyclic hydrocarbon groups, heterocyclic groups and phenylene groups, and A4 represents single bonds, carbonyl groups and aliphatic hydrocarbon groups. R1 and R2 represent hydrogen atoms, alkyl groups, cycloalkyl groups, phenyl groups and heterocyclic groups. The previously mentioned functional groups may be substituted.Type: GrantFiled: August 7, 2000Date of Patent: July 4, 2006Assignee: Teijin LimitedInventors: Satoshi Sugiura, Takaharu Tsutsumi, Yorimasa Suwa, Takami Arai, Katsutoshi Sakurai, Noboru Yoshioka, Akira Tanokura, Jun Suzuki
-
Publication number: 20050277773Abstract: The invention provides pyrrolo[3,2-d]pyrimidine derivatives represented by formula (I), and their medically acceptable salts. The compounds of the invention exhibit GSK-3 inhibiting activity and are therefore expected to be useful as therapeutic or prophylactic agents for conditions in which GSK-3 is implicated, such as diabetes, diabetes complications, Alzheimer's disease, neurodegenerative diseases, manic depression, traumatic encephalopathy, alopecia, inflammatory diseases, cancer and immune deficiency.Type: ApplicationFiled: February 24, 2003Publication date: December 15, 2005Inventors: Kenichiro Kataoka, Tomomi Kosugi, Toshihiro Ishii, Takahiro Takeuchi, Takaharu Tsutsumi, Akira Nakano, Gen Unoki, Masanori Yamamoto, Yuri Sakai
-
Publication number: 20050171094Abstract: A pyrrolo[3,2-d]pyrimidine derivative represented by the formula (I) or a pharamaceutically acceptable salt of the derivative. The derivative or salt is useful as a GSK-3 inhibitor.Type: ApplicationFiled: February 24, 2003Publication date: August 4, 2005Inventors: Kenichiro Kataoka, Tomomi Kosugi, Toshihiro Ishii, Takahiro Takeuchi, Takaharu Tsutsumi, Akira Nakano, Yoji Yamamoto, Noboru Yoshioka
-
Publication number: 20050153992Abstract: A compound having GSK-3 inhibiting function. A1 and A3 are a single bond, an aliphatic hydrocarbon group; A2 and A4 are a single bond, CO, COO, CONR, O, OCO, NR, NRCO, NRCOO, etc.; G1 is a single bond, an aliphatic hydrocarbon, aromatic hydrocarbon, heterocyclic; G2 is a hydrogen atom, an aliphatic hydrocarbon, an alicyclic hydrocarbon, an aromatic hydrocarbon, heterocyclic; A5 is a single bond, NR; R2 is H, halogen, an aliphatic hydrocarbon, alicyclic hydrocarbon, aromatic hydrocarbon, heterocyclic; A6 is a single bond, NR, CO, NRCO, NRCONR, CONR, COO, O, etc.; R3 is H, halogen, nitro, saturated aliphatic hydrocarbon, alicyclic hydrocarbon, aromatic hydrocarbon, heterocyclic; and when A6 is CR?CR or C?C; R3 may be a trimethylsilyl, formyl, acyl, carboxyl, alkoxylcarbonyl, carbamoyl, alkylcarbamoyl or cyano group; and R is H or an aliphatic hydrocarbon group.Type: ApplicationFiled: August 26, 2004Publication date: July 14, 2005Applicant: TEIJIN PHARMA LIMITEDInventors: Takaharu Tsutsumi, Satoshi Sugiura, Masahiro Koga, Yoshiyuki Matsumoto, Toshihiro Ishii, Akira Nakano, Gen Unoki, Yuri Sakai, Reiko Takarada, Hiroko Ogawa
-
Patent number: 6706745Abstract: The present invention relates to a biphenylamidine derivative of the general formula (1): or a pharmaceutically acceptable salt thereof, which is a novel compound functioning as a clinically applicable FXa inhibitor.Type: GrantFiled: May 18, 2000Date of Patent: March 16, 2004Assignee: Teijin LimitedInventors: Takayuki Hara, Tomohisa Nakada, Yasunobu Takano, Satoshi Sugiura, Takaharu Tsutsumi, Yoshiharu Takazawa, Reiko Takarada
-
Patent number: 6451842Abstract: A compound represented by the general formula (I), a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable C1-C6 alkyl addition salt thereof, and their medical applications. These compounds inhibit the action of chemokines such as MIP-1&agr; and/or MCP-1 on target cells, and are useful as therapeutic and/or preventative drugs in diseases, such as atherosclerosis, rheumatoid arthritis, and the like where blood monocytes and lymphocytes infiltrate into tissues.Type: GrantFiled: May 16, 2000Date of Patent: September 17, 2002Assignees: Dupont Pharmaceuticals Company, Teijin LimitedInventors: Tatsuki Shiota, Ken-ichiro Kataoka, Minoru Imai, Takaharu Tsutsumi, Masaki Sudoh, Ryo Sogawa, Takuya Morita, Takahiko Hada, Yumiko Muroga, Osami Takenouchi, Minoru Furuya, Noriaki Endo, Christine M. Tarby, Wilna Moree, Steven Teig
-
Patent number: 6410566Abstract: A compound represented by the general formula (I), a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable C1-C6 alkyl addition salt thereof, and their medical applications. These compounds inhibit the action of chemokines such as MIP-1&agr; and/or MCP-1 on target cells, and are useful as therapeutic and/or preventative drugs in diseases, such as atherosclerosis, rheumatoid arthritis, and the like where blood monocytes and lymphocytes infiltrate into tissues.Type: GrantFiled: July 16, 2001Date of Patent: June 25, 2002Assignees: Teijin Limited, Dupont Phamaceuticals CompanyInventors: Tatsuki Shiota, Ken-ichiro Kataoka, Minoru Imai, Takaharu Tsutsumi, Masaki Sudoh, Ryo Sogawa, Takuya Morita, Takahiko Hada, Yumiko Muroga, Osami Takenouchi, Minoru Furuya, Noriaki Endo, Christine M. Tarby, Wilna Moree, Steven Teig
-
Patent number: 6362177Abstract: A compound represented by the general formula (I), a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable C1-C6 alkyl addition salt thereof, and their medical applications. These compounds inhibit the action of chemokines such as MIP-1&agr; and/or MCP-1 on target cells, and are useful as therapeutic and/or preventative drugs in diseases, such as atheroclerosis, rheumatoid arthritis, and the like where blood monocytes and lymphocytes infiltrate into tissues.Type: GrantFiled: July 16, 2001Date of Patent: March 26, 2002Assignees: Teijin Limited, Dupont Pharmaceuticals Research LaboratoriesInventors: Tatsuki Shiota, Ken-ichiro Kataoka, Minoru Imai, Takaharu Tsutsumi, Masaki Sudoh, Ryo Sogawa, Takuya Morita, Takahiko Hada, Yumiko Muroga, Osami Takenouchi, Minoru Furuya, Noriaki Endo, Christine M. Tarby, Wilna Moree, Steven Teig
-
Patent number: 6348478Abstract: The present invention is a biphenylamidine derivative represented by the formula (1) or a pharmaceutically acceptable derivative thereof: and the biphenylamidine derivative or the pharmaceutically acceptable derivative thereof is a novel compound which can be used as a clinically applicable FXa inhibitor.Type: GrantFiled: May 15, 2000Date of Patent: February 19, 2002Assignee: Teijin LimitedInventors: Takayuki Hara, Tomohisa Nakada, Yasunobu Takano, Satoshi Sugiura, Takaharu Tsutsumi, Yoshiharu Takazawa, Reiko Takarada
-
Patent number: 5990346Abstract: A prostaglandin having formula (I), (II), or (III): ##STR1## a process of production thereof, and inhibitors of cell migration caused by chemokines containing (I) or (II) as an active ingredient.Type: GrantFiled: February 26, 1997Date of Patent: November 23, 1999Assignee: Teijin LimitedInventors: Kenichiro Kataoka, Toru Minoshima, Tatsuki Shiota, Takaharu Tsutsumi, Takahiko Hada, Hiroko Tanaka, Takuya Morita, Noriaki Endo